Role of autotaxin in systemic lupus erythematosus
暂无分享,去创建一个
T. Sawada | Y. Tsuchida | H. Shoda | K. Fujio
[1] M. Mayes,et al. A 24‐Week, Phase IIa, Randomized, Double‐Blind, Placebo‐Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis , 2023, Arthritis & rheumatology.
[2] A. Kwakernaak,et al. Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue. , 2022, Autoimmunity reviews.
[3] T. Sawada,et al. Autotaxin is a potential link between genetic risk factors and immunological disturbances of plasmacytoid dendritic cells in systematic lupus erythematosus , 2022, Lupus.
[4] A. Psarras,et al. Emerging concepts of type I interferons in SLE pathogenesis and therapy , 2022, Nature Reviews Rheumatology.
[5] G. Tsokos,et al. Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies. , 2022, Journal of autoimmunity.
[6] Kai-ming Dai,et al. Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer , 2022, Frontiers in Oncology.
[7] Xuetao Cao,et al. Dendritic cells in systemic lupus erythematosus: From pathogenesis to therapeutic applications. , 2022, Journal of autoimmunity.
[8] S. Narumiya,et al. LPA suppresses T cell function by altering the cytoskeleton and disrupting immune synapse formation , 2022, Proceedings of the National Academy of Sciences of the United States of America.
[9] I. Bruce,et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials , 2022, Annals of the Rheumatic Diseases.
[10] M. Kurano,et al. Urine autotaxin levels reflect the disease activity of sarcoidosis , 2022, Scientific Reports.
[11] Stephan Hasse,et al. Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus , 2022, Lupus Science & Medicine.
[12] Jie-Young Song,et al. Enpp2 Expression by Dendritic Cells Is a Key Regulator in Migration , 2021, Biomedicines.
[13] V. Aidinis,et al. Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target , 2021, Frontiers in Immunology.
[14] E. Pearce,et al. Plasmacytoid dendritic cell activation is dependent on coordinated expression of distinct amino acid transporters. , 2021, Immunity.
[15] V. Aidinis,et al. Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells , 2021, medRxiv.
[16] Xiaotian Zhang,et al. The Expression Regulation and Biological Function of Autotaxin , 2021, Cells.
[17] L. Arnaud,et al. Living with systemic lupus erythematosus in 2020: a European patient survey , 2021, Lupus Science & Medicine.
[18] M. Sumitani,et al. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis , 2021, Scientific Reports.
[19] M. Kurano,et al. Suppressing postcollection lysophosphatidic acid metabolism improves the precision of plasma LPA quantification , 2021, Journal of lipid research.
[20] M. Kurano,et al. Higher serum levels of autotaxin and phosphatidylserine‐specific phospholipase A1 in patients with lupus nephritis , 2020, International journal of rheumatic diseases.
[21] Long N Nguyen,et al. Emerging roles of lysophospholipids in health and disease. , 2020, Progress in lipid research.
[22] E. Gao,et al. Autotaxin inhibition reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction. , 2020, Journal of molecular and cellular cardiology.
[23] M. Kurano,et al. Urinary autotaxin concentrations are associated with kidney injury. , 2020, Clinica chimica acta; international journal of clinical chemistry.
[24] A. Tamori,et al. Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C , 2020, Journal of gastroenterology and hepatology.
[25] Joseph N. Pucella,et al. Plasmacytoid Dendritic Cells and Type I Interferon Promote Extrafollicular B Cell Responses to Extracellular Self-DNA. , 2020, Immunity.
[26] Shingo Yamamoto,et al. ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. , 2020, ACS medicinal chemistry letters.
[27] H. Zayed,et al. Dysregulation of Signaling Pathways Due to Differentially Expressed Genes From the B-Cell Transcriptomes of Systemic Lupus Erythematosus Patients – A Bioinformatics Approach , 2020, Frontiers in Bioengineering and Biotechnology.
[28] Louise P Nichilatti,et al. Physiopathology of pain in systemic erythematosus lupus , 2020, Lupus.
[29] Systemic Lupus Erythematosus Disease Activity Index , 2020, Definitions.
[30] I. Bruce,et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. , 2019, The New England journal of medicine.
[31] V. Aidinis,et al. Autotaxin and chronic inflammatory diseases. , 2019, Journal of autoimmunity.
[32] M. Wuest,et al. Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer , 2019, Molecular Cancer Therapeutics.
[33] M. Ward,et al. EULAR recommendations for the management of antiphospholipid syndrome in adults , 2019, Annals of the rheumatic diseases.
[34] M. Kurano,et al. Autotaxin and soluble IL-2 receptor concentrations in cerebrospinal fluids are useful for the diagnosis of central nervous system invasion caused by haematological malignancies , 2019, Annals of clinical biochemistry.
[35] T. Denning,et al. Autotaxin determines colitis severity in mice and is secreted by B cells in the colon , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] M. Sumitani,et al. Lysophosphatidic acid is associated with neuropathic pain intensity in humans: An exploratory study , 2018, PloS one.
[37] S. Dupont,et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. , 2018, The Lancet. Respiratory medicine.
[38] K. Koike,et al. Performance of autotaxin as a serum marker for liver fibrosis , 2018, Annals of clinical biochemistry.
[39] N. Tanaka,et al. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease , 2018, World journal of gastroenterology.
[40] J. Wren,et al. Systemic lupus erythematosus biomarkers: the challenging quest , 2016, Rheumatology.
[41] M. Crow,et al. Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus. , 2016, Clinical immunology.
[42] Ranjan Gupta,et al. Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity , 2016, Clinical Rheumatology.
[43] Jianghua Chen,et al. Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses , 2016, PloS one.
[44] R. Lafyatis,et al. An Autotaxin/Lysophosphatidic Acid/Interleukin‐6 Amplification Loop Drives Scleroderma Fibrosis , 2016, Arthritis & rheumatology.
[45] Y. H. Lee,et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis , 2016, Lupus.
[46] N. Shen,et al. Predominant Role of Plasmacytoid Dendritic Cells in Stimulating Systemic Autoimmunity , 2015, Front. Immunol..
[47] Ming Guan,et al. Type I Interferons Function as Autocrine and Paracrine Factors to Induce Autotaxin in Response to TLR Activation , 2015, PloS one.
[48] T. Kinashi,et al. Autotaxin Produced by Stromal Cells Promotes LFA-1–Independent and Rho-Dependent Interstitial T Cell Motility in the Lymph Node Paracortex , 2014, The Journal of Immunology.
[49] S. Georas,et al. Regulation of T Cell Motility In Vitro and In Vivo by LPA and LPA2 , 2014, PloS one.
[50] Y. Fujiwara,et al. Lysophosphatidic Acid Receptor 5 Inhibits B Cell Antigen Receptor Signaling and Antibody Response , 2014, The Journal of Immunology.
[51] H. Ovaa,et al. Necessity of lysophosphatidic acid receptor 1 for development of arthritis. , 2013, Arthritis and rheumatism.
[52] Takao Shimizu,et al. Decrease in circulating autotaxin by oral administration of prednisolone. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[53] H. Ikeda,et al. Autotaxin in liver fibrosis. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[54] Yi-Chun Chen,et al. Autotaxin through Lysophosphatidic Acid Stimulates Polarization, Motility, and Transendothelial Migration of Naive T Cells , 2012, The Journal of Immunology.
[55] B. Rovin,et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. , 2012, Arthritis and rheumatism.
[56] M. Masu,et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis , 2012, The Journal of experimental medicine.
[57] S. Kōzuma,et al. Serum autotaxin measurements in pregnant women: application for the differentiation of normal pregnancy and pregnancy-induced hypertension. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[58] Tao Wu,et al. Binding of Autotaxin to Integrins Localizes Lysophosphatidic Acid Production to Platelets and Mammalian Cells* , 2011, The Journal of Biological Chemistry.
[59] P. Valet,et al. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid , 2011, Journal of Lipid Research.
[60] A. Skol,et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus , 2010, Arthritis research & therapy.
[61] Steve Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[62] M. Kurokawa,et al. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma , 2008, British journal of haematology.
[63] Y. Yatomi,et al. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity , 2008, Annals of clinical biochemistry.
[64] M. Gunn,et al. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs , 2008, Nature Immunology.
[65] M. Nangaku,et al. Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[66] H. Ikeda,et al. Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids. , 2007, Analytical biochemistry.
[67] Kazuhiro Nakamura,et al. Both Plasma Lysophosphatidic Acid and Serum Autotaxin Levels are Increased in Chronic Hepatitis C , 2007, Journal of clinical gastroenterology.
[68] S. Georas,et al. Lysophosphatidic acid modulates the activation of human monocyte-derived dendritic cells. , 2006, Stem cells and development.
[69] L. Rönnblom,et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. , 2004, Arthritis and rheumatism.
[70] T. Giese,et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. , 2004, Blood.
[71] Virginia Pascual,et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. , 2003, Immunity.
[72] F. Di Virgilio,et al. The Influence of Lysophosphatidic Acid on the Functions of Human Dendritic Cells , 2002, The Journal of Immunology.
[73] D. Gladman,et al. Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.
[74] V. Pascual,et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. , 2001, Science.
[75] M Markman,et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. , 1998, JAMA.
[76] T. Schnitzer,et al. Serum interferon levels in patients with systemic lupus erythematosus. , 1982, Arthritis and rheumatism.
[77] A. Notkins,et al. Immune interferon in the circulation of patients with autoimmune disease. , 1979, The New England journal of medicine.